Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973319 | 0.72 | ESR1 (0.50) | CA12CA1CA9TSHRHIF1A | |
| SCHEMBL7670364 | 0.65 | PGK1 (0.35) | — | |
| SCHEMBL2050376 | 0.65 | GABRA1 (0.48) | BACE1CA1CA9TSHRHIF1A | |
| SCHEMBL23888768 | 0.63 | CA12 (0.57) | BACE1CA12CA1CA9 | |
| SCHEMBL30225640 | 0.63 | CA12 (0.57) | BACE1CA12CA1CA9 | |
| SCHEMBL28900423 | 0.63 | GABRA1 (0.46) | BACE1CA1CA9TSHRHIF1A | |
| SCHEMBL2340744 | 0.62 | CYP3A4 (0.35) | BACE1CA12CA1CA9TSHR | |
| SCHEMBL21551002 | 0.62 | HCAR1 (0.40) | BACE1CA12CA1CA9TSHR | |
| SCHEMBL30931765 | 0.62 | HCAR1 (0.40) | BACE1CA12CA1CA9TSHR | |
| SCHEMBL30994395 | 0.62 | ALDH1A1 (0.55) | BACE1CA12CA1CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | HCAR1, HCAR3, CYP2C9 | BACE1 3873/4885CA12 2677/4885CA1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.